| All Releases |
 |
Sunesis Pharmaceuticals Reports Financial Results for the Second Quarter 2008
Aug 7, 2008
|
20.0 KB |
| |
SOUTH SAN FRANCISCO, Calif., Aug 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today reported financial results for the quarter ended June 30, 2008.
Total revenue ...
|
|
Sunesis Pharmaceuticals to Report Financial Results for the Second Quarter on August 7, 2008
Jul 29, 2008
|
8.7 KB |
| |
SOUTH SAN FRANCISCO, Calif., July 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of new oncology therapeutics, today announced that management will hold an investor conference call on Thursday, August...
|
|
Sunesis Pharmaceuticals to Present at the Collins Stewart Fourth Annual Growth Conference
Jul 3, 2008
|
8.5 KB |
| |
SOUTH SAN FRANCISCO, Calif., July 3, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Daniel Swisher, Sunesis' Chief Executive Officer and President, will provide a corporate overview at the upcoming Collins Stewart Fourth Annual Growth Conference at 2:30 p.m. Eastern Time on J...
|
|
Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
Jun 19, 2008
|
8.5 KB |
| |
SOUTH SAN FRANCISCO, Calif., June 19, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Eric Bjerkholt, Sunesis' Senior Vice President, Corporate Development and Finance, will provide a corporate update at the upcoming Jefferies 2nd Annual Healthcare Conference at 2:00 p.m. East...
|
|
Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
Jun 16, 2008
|
15.1 KB |
| |
SOUTH SAN FRANCISCO, Calif., June 16, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) presented data Saturday from two clinical trials of the company's lead drug candidate, voreloxin (formerly SNS-595), including updated results of a Phase 1 trial of voreloxin when used as a single agent in relaps...
|
|
Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
Jun 3, 2008
|
15.5 KB |
| |
SOUTH SAN FRANCISCO, Calif., June 3, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a corporate realignment to focus on the development of the company's lead oncology product candidate, voreloxin (formerly SNS-595). In conjunction with this strategic restructuring, Sunesis expande...
|
|
Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
Jun 3, 2008
|
14.1 KB |
| |
SOUTH SAN FRANCISCO, Calif., June 3, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the expansion of its late-stage development leadership team with the appointment of industry veterans Steven B. Ketchum, Ph.D., as Senior Vice President, Research and Development and Mary G. Bolton...
|
|
Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
May 31, 2008
|
13.7 KB |
| |
SOUTH SAN FRANCISCO, Calif., May 31, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today presented an update of interim data from the company's ongoing Phase 2 clinical trial of its lead product candidate, voreloxin (formerly SNS-595), in platinum-resistant ovarian cancer patients at the 44th Am...
|
|
Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
May 28, 2008
|
11.7 KB |
| |
SOUTH SAN FRANCISCO, Calif., May 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) will present data from ongoing clinical trials of voreloxin (formerly SNS-595) at two major upcoming oncology conferences.
Updated interim data from Sunesis' ongoing Phase 2 clinical trial of voreloxin in plat...
|
|
Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
May 21, 2008
|
13.4 KB |
| |
SOUTH SAN FRANCISCO, Calif., May 21, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the initiation of the REVEAL-1 (Response Evaluation of Voreloxin in Elderly AML) Phase 2 clinical trial of voreloxin (also known as SNS-595), the company's lead anti-cancer therapeutic. The REVEAL-...
|
|
Sunesis Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
May 13, 2008
|
8.6 KB |
| |
SOUTH SAN FRANCISCO, Calif., May 13, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Eric Bjerkholt, Sunesis' Senior Vice President, Corporate Development and Finance, will provide a corporate update at the upcoming Rodman & Renshaw 5th Annual Global Healthcare Conference at 9...
|
|
Sunesis Pharmaceuticals Reports First Quarter 2008 Financial Results
May 8, 2008
|
19.6 KB |
| |
SOUTH SAN FRANCISCO, Calif., May 8, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics, today reported financial results for the quarter ended March 31, 2008.
...
|
|
Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
Apr 30, 2008
|
8.8 KB |
| |
SOUTH SAN FRANCISCO, Calif., April 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics, today announced that management will hold an investor conference call...
|
|
Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
Apr 16, 2008
|
12.3 KB |
| |
SOUTH SAN FRANCISCO, Calif., April 16, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported data from nonclinical studies of SNS-032 in multiple myeloma and mantle cell lymphoma. Data from studies conducted in collaboration with the Multiple Myeloma Research Consortium (MMRC) and with th...
|
|
Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
Apr 14, 2008
|
13.2 KB |
| |
SOUTH SAN FRANCISCO, Calif., April 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today presented nonclinical data on SNS-595's unique mechanism of action and its anticancer activity at the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, CA. A Phase 2 singl...
|
|
Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
Apr 9, 2008
|
11.9 KB |
| |
SOUTH SAN FRANCISCO, Calif., April 9, 2008, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the company will present data on each of its clinical-stage anticancer compounds at the upcoming Annual Meeting of the American Association for Cancer Research (AACR) being held April 1...
|
|
Sunesis Pharmaceuticals to Present at Healthcare Investor Conferences in March
Mar 13, 2008
|
8.8 KB |
| |
SOUTH SAN FRANCISCO, Calif., March 13, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Daniel Swisher, Sunesis' Chief Executive Officer and President, will provide a corporate overview at two upcoming investor conferences in March.
-- Mr. Swisher will speak at the Co...
|
|
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Mar 11, 2008
|
21.7 KB |
| |
SOUTH SAN FRANCISCO, Calif., March 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics, today reported financial results for the quarter and fiscal year ende...
|
|
Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
Mar 10, 2008
|
13.5 KB |
| |
SOUTH SAN FRANCISCO, Calif., March 10, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics, today announced positive interim data from the company's ongoing Phas...
|
|
Sunesis Pharmaceuticals to Report Fourth Quarter and Full-Year 2007 Financial Results on March 11, 2008
Mar 5, 2008
|
8.8 KB |
| |
SOUTH SAN FRANCISCO, Calif., March 5, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company developing novel anticancer therapeutics, today announced that management will hold an investor conference call on Tuesday, March 11, 2008 at 10:30 a.m. ET/7:30 a.m. PT...
|
|
|
